1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest . 2007;117(3):557-567
2. Matucci-Cerinic M, Steen VD, Furst DE, Seibold JR. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther . 2007;9 Suppl 2:S7.
3. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther . 2007;9 suppl 2:S4.
4. Scleroderma Foundation. What is scleroderma? www.scleroderma.org/medical/overview.shtm. Accessed February 20, 2009.
5. American College of Rheumatology. Scleroderma (systemic sclerosis). www.rheumatology.org/public/factsheets/diseases_and_conditions/scleroderma .asp. Accessed February 20, 2009.
6. Chatterjee S. Systemic sclerosis (2002). www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/rheumatology/scleroderma/scleroderma.htm. Accessed February 20, 2009.
7. du Bois RM. Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc . 2007;4(5):434-438.
8. Ostojic P, Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol . 2006;25(4):453-457.
9. Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum . 2001;44(3):735-736.
10. Haustein UF. Systemic sclerosis—scleroderma (2002). Dermatol Online J . 8(1):3. http://dermatology.cdlib.org/DOJvol8num1/reviews/scleroderma/haustein.html. Accessed February 20, 2009.
11. Raynaud’s and Scleroderma Association. Scleroderma. www.raynauds.org.uk/potioncms/viewer.asp?a=31&z=13. Accessed February 20, 2009.
12. Moore SC, Desantis ER. Treatment of complications associated with systemic sclerosis. Am J Health Syst Pharm . 2008;65(4):315-321.
13. Launay D, Diot E, Pasquier E, et al. Bosentan for treatment of active digital ulcers in patients with systemic sclerosis (9 cases) [in French]. Presse Med . 2006;35(4 pt 1):587-592.
14. Schwartz RA, Dziankowska-Bartkowiak B, Zalewska A, Sysa-Jedrzejowska A. Systemic sclerosis. www.emedicine.com/derm/topic677.htm. Accessed February 20, 2009.
15. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum . 2006; 54(11):3655-3660.
16. Ahathya RS, Deepalakshmi D, Emmadi P. Systemic sclerosis. Indian J Dent Res . 2007;18(1):27-30.
17. Allali F, Tahiri L, Senjari A, et al. Erosive arthropathy in systemic sclerosis. BMC Public Health . 2007;7:260.
18. Wipff J, Allanore Y, Soussi F, et al. Prevalence in Barrett’s esophagus in systemic sclerosis. Arthritis Rheum . 2005;52(9):2882-2888.
19. Osada T, Nagahara A, Ishikawa D, et al. Diaphragm-like stricture in the duodenum in a patient with systemic sclerosis: unrelated to non-steroidal anti-inflammatory drug use. Intern Med . 2007;46(20):1697-1700.
20. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis . 1998; 57:682-686.
21. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM . 2007;100(8):485-494.
22. de Vijlder HC, Ter Borg EJ. A patient with acute renal failure: scleroderma crisis (SRC). Neth J Med . 2007;65(9):360-361.
23. Bashandy HG, Javillo JS, Gambert SR. A case of early onset normotensive scleroderma renal crisis in a patient with diffuse cutaneous systemic sclerosis. South Med J . 2006;99(8):870-872.
24. Medsger TA Jr, Rodriguez-Reyna TS. Scleroderma renal crisis: a high index of suspicion speeds diagnosis and life-saving treatment. South Med J . 2006; 99(8):799-800.
25. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med . 2000; 133(8):600-603.
26. Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum . 2006;54(12):3971-3978.
27. Uziel Y, Feldman BM, Krafchik BR, et al. Increased serum levels of TGFb1 in children with localized scleroderma. Pediatr Rheumatol Online J . 2007;5:22.
28. Fonseca C, Denton CP. Genetic association studies in systemic sclerosis: more evidence of a complex disease. J Rheumatol . 2007;34(5):903-905.
29. Mayes MD, Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther . 2007;9 suppl 2:S5.
30. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther . 2007;9 Suppl 2:S2.
31. Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford) . 2007;46(5):833-841.
32. Avouac J, Sordet C, Depinay C, et al. Systemic sclerosis–associated Sjogren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum . 2006;54(7): 2243-2249.
33. Fischer A, Meehan RT, Feghali-Bostwick CA. et al. Unique characteristics of systemic sclerosis sine scleroderma–associated interstitial lung disease. Chest . 2006;130(4):976-981.
34. Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med . 1997;103(3): 242-248.
35. Wozniak J, Dabrowski R, Luczak D, et al. Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma. J Rheumatol . 2009;36(1):191-196.
36. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum . 1980;23(5):581-590.
37. Johnson SR, Laxer RM. Classification in systemic sclerosis. J Rheumatol . 2006;33(5):840-841.
38. Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit . 2004;10(11):CR615-CR621.
39. Denton CP. Therapeutic targets in systemic sclerosis. Arthritis Res Ther . 2007;9 suppl 2:S6.
40. Rubin LJ, Black CM, Denton CP, Seibold JR. Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. Arthritis Res Ther . 2007;9 Suppl 2:S10.
41. Akerkar SM, Bichile LS. Therapeutic options for systemic sclerosis. Indian J Dermatol Venereol Leprol . 2004;70(2):67-75.
42. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol . 1996; 34(4):364-372.
43. Roman A, Gispert P, Monforte V, et al. Long-term outcomes of treatment with bosentan in pulmonary hypertension [in Spanish]. Arch Bronconeumol . 2006;42(12):616-620.